• 1
    Horlein H. The chemotherapy of infectious diseases caused by protozoa and bacteria (Section of Tropical Diseases and Parasitology). Proc R Soc Med 1936; 29: 313324.
  • 2
    Sulphonamide treatment. BMJ 1943; 2: 204205.
  • 3
    Roth B, Falco EA, Hitchings GH, Bushby SR. 5-Benzyl-2,4-diaminopyrimidines as antibacterial agents. I. Synthesis and antibacterial activity in vitro. J Med Pharm Chem 1962; 91: 11031123.
  • 4
    Darrell JH, Garrod LP, Waterworth PM. Trimethoprim: laboratory and clinical studies. J Clin Pathol 1968; 21: 202209.
  • 5
    Reeves DS. Sulphamethoxazole–trimethoprim: the first two years. J Clin Pathol 1971; 24: 430437.
  • 6
    Huovinen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis 1997; 24 (suppl 1): S63S66.
  • 7
    Wallace RJ Jr, Septimus EJ, Musher DM, Martin RR. Disk diffusion susceptibility testing of Nocardia species. J Infect Dis 1977; 135: 568576.
  • 8
    Ramam M, Bhat R, Garg T et al. A modified two-step treatment for actinomycetoma. Indian J Dermatol Venereol Leprol 2007; 73: 235239.
  • 9
    Ramam M, Garg T, D’Souza P et al. A two-step schedule for the treatment of actinomycotic mycetomas. Acta Derm Venereol 2000; 80: 378380.
  • 10
    Kuijper EJ, Peeters MF, Schoenmakers BS, Zanen HC. Antimicrobial susceptibility of sixty human fecal isolates of Aeromonas species. Eur J Clin Microbiol Infect Dis 1989; 8: 248250.
  • 11
    Vila J, Ruiz J, Gallardo F et al. Aeromonas spp. and traveler’s diarrhea: clinical features and antimicrobial resistance. Emerg Infect Dis 2003; 9: 552555.
  • 12
    Larka UB, Ulett D, Garrison T, Rockett MS. Aeromonas hydrophila infections after penetrating foot trauma. J Foot Ankle Surg 2003; 42: 8305.
  • 13
    Tena D, Gonzalez-Praetorius A, Perez-Balsalobre M, Sancho O, Bisquert J. Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases. Scand J Infect Dis 2008; 40: 8487.
  • 14
    Legrand C, Anaissie E. Bacteremia due to Achromobacter xylosoxidans in patients with cancer. Clin Infect Dis 1992; 14: 479484.
  • 15
    Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection 2010; 38: 211215.
  • 16
    Gopalakrishnan R, Hawley HB, Czachor JS, Markert RJ, Bernstein JM. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals: a study of 143 patients. Heart Lung 1999; 28: 134141.
  • 17
    Bin Abdulhak AA, Zimmerman V, Al Beirouti BT, Baddour LM, Tleyjeh IM. Stenotrophomonas maltophilia infections of intact skin: a systematic review of the literature. Diagn Microbiol Infect Dis 2009; 63: 330333.
  • 18
    Al-Jasser AM. Stenotrophomonas maltophilia resistant to trimethoprim–sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 2006; 5: 2325.
  • 19
    Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ 2008; 336: 701704.
  • 20
    Shehabi A, Shakir K, el-Khateeb M, Qubain H, Fararjeh N, Shamat AR. Diagnosis and treatment of 106 cases of human brucellosis. J Infect 1990; 20: 510.
  • 21
    Khan MY, Mah MW, Memish ZA. Brucellosis in pregnant women. Clin Infect Dis 2001; 32: 11721177.
  • 22
    Roushan MR, Gangi SM, Ahmadi SA. Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis. Swiss Med Wkly 2004; 134: 564568.
  • 23
    Takagi T, Nagai H, Kobayashi M, Shinagawa N. Pseudomonas cepacia meningitis: report of 3 cases. No Shinkei Geka 1982; 10: 8388.
  • 24
    Noriega ER, Rubinstein E, Simberkoff MS, Rahal JJ. Subacute and acute endocarditis due to Pseudomonas cepacia in heroin addicts. Am J Med 1975; 59: 2936.
  • 25
    Chaowagul W, Chierakul W, Simpson AJ et al. Open-label randomized trial of oral trimethoprim–sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim–sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents Chemother 2005; 49: 40204025.
  • 26
    Chetchotisakd P, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B. Randomized, double-blind, controlled study of cefoperazone–sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis. Clin Infect Dis 2001; 33: 2934.
  • 27
    Fernandez-Sabe N, Cervera C, Lopez-Medrano F et al. Risk factors, clinical features, and outcomes of listeriosis in solid-organ transplant recipients: a matched case–control study. Clin Infect Dis 2009; 49: 11531159.
  • 28
    Merle-Melet M, Dossou-Gbete L, Maurer P et al. Is amoxicillin–cotrimoxazole the most appropriate antibiotic regimen for listeria meningoencephalitis? Review of 22 cases and the literature. J Infect 1996; 33: 7985.
  • 29
    Coyle PV, Thompson J, Adgey AA et al. Changes in circulating immune complex concentrations and antibody titres during treatment of Q fever endocarditis. J Clin Pathol 1985; 38: 743746.
  • 30
    Carcopino X, Raoult D, Bretelle F, Boubli L, Stein A. Managing Q fever during pregnancy: the benefits of long-term cotrimoxazole therapy. Clin Infect Dis 2007; 45: 548555.
  • 31
    Feurle GE, Junga NS, Marth T. Efficacy of ceftriaxone or meropenem as initial therapies in Whipple’s disease. Gastroenterology 2009; 138: 478486; quiz 11–12.
  • 32
    Durand DV, Lecomte C, Cathebras P, Rousset H, Godeau P. Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Societe Nationale Francaise de Medecine Interne. Medicine (Baltimore) 1997; 76: 170184.
  • 33
    Feurle GE, Marth T. An evaluation of antimicrobial treatment for Whipple’s disease. Tetracycline versus trimethoprim–sulfamethoxazole. Dig Dis Sci 1994; 39: 16421648.
  • 34
    Lagier JC, Fenollar F, Lepidi H, Raoult D. Failure and relapse after treatment with trimethoprim/sulfamethoxazole in classic Whipple’s disease. J Antimicrob Chemother 2010; 65: 20052012.
  • 35
    Garg BR, Lal S, Sivamani S. Efficacy of co-trimoxazole in donovanosis. A preliminary report. Br J Vener Dis 1978; 54: 348349.
  • 36
    Lal S, Garg BR. Further evidence of the efficacy of co-trimoxazole in granuloma venereum. Br J Vener Dis 1980; 56: 412413.
  • 37
    Birthistle K, Greig J, Hay P. Failure of trimethoprim in the treatment of donovanosis. Genitourin Med 1997; 73: 224225.
  • 38
    O’Farrell N, Moi H. European guideline for the management of donovanosis, 2010. Int J STD AIDS 2010; 21: 609610.
  • 39
    Goldberg E, Paul M, Talker O et al. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. J Antimicrob Chemother 2010; 65: 17791783.
  • 40
    Kaka AS, Rueda AM, Shelburne SA 3rd, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 680683.
  • 41
    Bishara J, Pitlik S, Samra Z, Levy I, Paul M, Leibovici L. Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988–1997. Emerg Infect Dis 2003; 9: 11681169.
  • 42
    Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5: 210.
  • 43
    Tsuji BT, Rybak MJ, Cheung CM, Amjad M, Kaatz GW. Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. Diagn Microbiol Infect Dis 2007; 58: 4147.
  • 44
    Kimura A, Mochizuki T, Nishizawa K, Mashiko K, Yamamoto Y, Otsuka T. Trimethoprim–sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients. J Trauma 1998; 45: 383387.
  • 45
    Schmitz GR, Bruner D, Pitotti R et al. Randomized controlled trial of trimethoprim–sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Ann Emerg Med 2010; 56: 283287.
  • 46
    Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med 2009; 55: 401407.
  • 47
    Tong SY, Andrews RM, Kearns T et al. Trimethopim–sulfamethoxazole compared with benzathine penicillin for treatment of impetigo in Aboriginal children: a pilot randomised controlled trial. J Paediatr Child Health 2010; 46: 131133.
  • 48
    Euba G, Murillo O, Fernandez-Sabe N et al. Long-term follow-up trial of oral rifampin–cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009; 53: 26722676.
  • 49
    Cenizal MJ, Skiest D, Luber S et al. Prospective randomized trial of empiric therapy with trimethoprim–sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 26282630.
  • 50
    Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim–sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390398.
  • 51
    Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, Roberts GD. Tuberculosis and trimethoprim–sulfamethoxazole. Antimicrob Agents Chemother 2009; 53: 47894793.
  • 52
    Sandison TG, Homsy J, Arinaitwe E et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ 2011; 342: d1617 (1–10).
  • 53
    Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald M, Mwapasa V. Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine–pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J Infect Dis 2011; 203: 464472.
  • 54
    Mermin J, Ekwaru JP, Liechty CA et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367: 12561261.
  • 55
    Genton B, Mueller I, Betuela I et al. Rifampicin/cotrimoxazole/isoniazid versus mefloquine or quinine + sulfadoxine–pyrimethamine for malaria: a randomized trial. PLoS Clin Trials 2006; 1: e38.
  • 56
    Goerg H, Ochola SA, Goerg R. Treatment of malaria tropica with a fixed combination of rifampicin, co-trimoxazole and isoniazid: a clinical study. Chemotherapy 1999; 45: 6876.
  • 57
    Fehintola FA, Balogun ST. Comparative study of efficacy of artesunate plus cotrimoxazole and artesunate plus chloroquine in the treatment of malaria in Nigerian children: a preliminary report. J Vector Borne Dis 2010; 47: 145150.
  • 58
    Fehintola FA, Adedeji AA, Gbotosho GO et al. Effects of artesunate–cotrimoxazole and amodiaquine–artesunate against asexual and sexual stages of Plasmodium falciparum malaria in Nigerian children. J Infect Chemother 2008; 14: 188194.
  • 59
    Hamel MJ, Holtz T, Mkandala C et al. Efficacy of trimethoprim–sulfamethoxazole compared with sulfadoxine–pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. Am J Trop Med Hyg 2005; 73: 609615.
  • 60
    Fehintola FA, Adedeji AA, Tambo E, Fateye BB, Happi TC, Sowunmi A. Cotrimoxazole in the treatment of acute uncomplicated falciparum malaria in Nigerian children : a controlled clinical trial. Clin Drug Investig 2004; 24: 149155.
  • 61
    Omar SA, Bakari A, Owiti A, Adagu IS, Warhurst DC. Co-trimoxazole compared with sulfadoxine–pyrimethamine in the treatment of uncomplicated malaria in Kenyan children. Trans R Soc Trop Med Hyg 2001; 95: 657660.
  • 62
    Lal H. A comparative trial of oral chloroquine and oral co-trimoxazole in vivax malaria in children. Am J Trop Med Hyg 1982; 31 (3 Pt 1): 438440.
  • 63
    Fung KT, Dhillon AP, McLaughlin JE et al. Cure of Acanthamoeba cerebral abscess in a liver transplant patient. Liver Transpl 2008; 14: 308312.
  • 64
    Singhal T, Bajpai A, Kalra V et al. Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials. Pediatr Infect Dis J 2001; 20: 623627.
  • 65
    Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW. Trimethoprim–sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 2000; 132: 885888.
  • 66
    Pape JW, Verdier RI, Johnson WD Jr. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 10441047.
  • 67
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 120; 7 quiz CE1–CE4.
  • 68
    Madico G, McDonald J, Gilman RH, Cabrera L, Sterling CR. Epidemiology and treatment of Cyclospora cayetanensis infection in Peruvian children. Clin Infect Dis 1997; 24: 977981.
  • 69
    Hoge CW, Shlim DR, Ghimire M et al. Placebo-controlled trial of co-trimoxazole for Cyclospora infections among travellers and foreign residents in Nepal. Lancet 1995; 345: 691693.